Valuation: Mirum Pharmaceuticals, Inc.

Market Cap 7.25B 6.33B 5.85B 5.39B 10.15B 698B 10.38B 69.86B 27.48B 342B 27.22B 26.62B 1,177B P/E 2026 *
-7.6x
P/E 2027 * -182x
Enterprise Value 7.28B 6.36B 5.87B 5.41B 10.2B 701B 10.43B 70.2B 27.61B 343B 27.35B 26.75B 1,182B EV / Sales 2026 *
10.8x
EV / Sales 2027 * 8.82x
Free-Float
98.41%
Yield 2026 *
-
Yield 2027 * -
1 day+1.28%
1 week-2.68%
Current month+1.53%
1 month+16.48%
3 months+21.35%
6 months+30.54%
Current year+50.47%
1 week 113
Extreme 113
121.82
1 month 105.18
Extreme 105.18
130
Current year 73.82
Extreme 73.82
130
1 year 50.25
Extreme 50.25
130
3 years 23.14
Extreme 23.14
130
5 years 12.82
Extreme 12.82
130
10 years 6.51
Extreme 6.5126
130
Manager TitleAgeSince
Chief Executive Officer 47 2019-03-20
Director of Finance/CFO 66 2023-09-10
President 48 2024-01-15
Director TitleAgeSince
Chairman 73 2019-03-20
Director/Board Member 55 2018-11-06
Director/Board Member 47 2018-10-31
Date Insider Type Main position Quantity % Market Cap.
7/6/26 Fiscal year

Founder

60,000 0.0984%
7/6/26 Sell

Chief Financial Officer

-5,000 0.0082%
7/1/26 Sell

Controller/Auditor

-2,721 0.0045%
Change 5-day change 1-year change 3-year change Capi.($)
+1.28%-2.68%+125.41%+337.95% 7.25B
+0.85%-0.80%+54.84%+163.70% 1,051B
+1.23%-1.53%+55.26%+59.07% 609B
+0.04%+2.58%+32.96%+88.75% 450B
+0.78%-0.71%+30.04%+24.61% 330B
+1.41%+0.58%+33.92%+47.20% 284B
-0.27%-1.87%+22.13%+23.47% 263B
-1.76%+2.37%-22.19%-38.45% 223B
-1.42%+0.80%+22.81%+60.77% 198B
-1.48%+3.43%+23.42%+73.31% 167B
Average +0.02%+0.22%+37.86%+84.04% 358.23B
Weighted average by Cap. +0.22%+0.02%+37.93%+82.01%

Financials

2026 *2027 *
Net sales 675M 590M 545M 502M 946M 65.03B 967M 6.51B 2.56B 31.85B 2.54B 2.48B 110B 815M 712M 657M 606M 1.14B 78.5B 1.17B 7.86B 3.09B 38.45B 3.06B 2.99B 132B
Net income -910M -795M -734M -676M -1.27B -87.61B -1.3B -8.77B -3.45B -42.91B -3.42B -3.34B -148B -1.62M -1.42M -1.31M -1.21M -2.27M -156M -2.32M -15.63M -6.15M -76.5M -6.09M -5.96M -263M
Net Debt 34.69M 30.31M 27.97M 25.78M 48.6M 3.34B 49.68M 334M 132M 1.64B 130M 127M 5.63B -61.06M -53.36M -49.24M -45.39M -85.55M -5.88B -87.45M -589M -231M -2.88B -229M -224M -9.91B
Logo Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Employees
418
Date Price Change Volume
26-07-17 US$118.86 +1.28% 435,890
26-07-16 US$117.36 -3.01% 424,645
26-07-15 US$121.00 +0.09% 316,557
26-07-14 US$120.89 +1.55% 714,994
26-07-13 US$119.04 -2.53% 601,198
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
118.86USD
Average target price
146.50USD
Spread / Average Target
+23.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MIRM Stock